Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Bremell

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
International Journal of Radiation Oncology, Biology, Physics|May 8, 2014
Neurochemical evidence of potential neurotoxicity after prophylactic cranial irradiationMarie Kalm, Edvard Abel, Pontus Wasling, et al.
Biochemical and Biophysical Research Communications|August 17, 2011
The N-terminal domain of α-dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosisCamilla Hesse, Inger Johansson, Niklas Mattsson, et al.
International Journal of Cancer|March 10, 2005
Chlamydia trachomatis infection and persistence of human papillomavirusIlvars Silins, Walter Ryd, Anders Strand, et al.
JAMA Network Open|May 23, 2022
Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic SymptomsArvid Edén, Anna Grahn, Daniel Bremell, et al.
The Journal of Infectious Diseases|October 24, 2023
COVID-19 Recovery: Consistent Absence of Cerebrospinal Fluid Biomarker Abnormalities in Patients With Neurocognitive Post-COVID ComplicationsNelly Kanberg, Anna Grahn, Erika Stentoft, et al.
Infection|April 17, 2025
Towards shortening the duration of antibiotic therapy for Lyme borreliosis: a systematic review and meta-analysisAlice Raffetin, Anna J Henningsson, Katharina Ornstein, et al.
Trials|March 17, 2021
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trialKarin Welén, Anna K Överby, Clas Ahlm, et al.
European Urology|January 4, 2022
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro DataKarin Welén, Ebba Rosendal, Magnus Gisslén, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
International Journal of Radiation Oncology, Biology, Physics|May 8, 2014
Neurochemical evidence of potential neurotoxicity after prophylactic cranial irradiationMarie Kalm, Edvard Abel, Pontus Wasling, et al.
Biochemical and Biophysical Research Communications|August 17, 2011
The N-terminal domain of α-dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosisCamilla Hesse, Inger Johansson, Niklas Mattsson, et al.
International Journal of Cancer|March 10, 2005
Chlamydia trachomatis infection and persistence of human papillomavirusIlvars Silins, Walter Ryd, Anders Strand, et al.
JAMA Network Open|May 23, 2022
Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic SymptomsArvid Edén, Anna Grahn, Daniel Bremell, et al.
The Journal of Infectious Diseases|October 24, 2023
COVID-19 Recovery: Consistent Absence of Cerebrospinal Fluid Biomarker Abnormalities in Patients With Neurocognitive Post-COVID ComplicationsNelly Kanberg, Anna Grahn, Erika Stentoft, et al.
Infection|April 17, 2025
Towards shortening the duration of antibiotic therapy for Lyme borreliosis: a systematic review and meta-analysisAlice Raffetin, Anna J Henningsson, Katharina Ornstein, et al.
Trials|March 17, 2021
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trialKarin Welén, Anna K Överby, Clas Ahlm, et al.
European Urology|January 4, 2022
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro DataKarin Welén, Ebba Rosendal, Magnus Gisslén, et al.
Pageof 3